AIM Vaccine Statistics

Total Valuation

AIM Vaccine has a market cap or net worth of HKD 7.08 billion. The enterprise value is 8.75 billion.

Market Cap	7.08B
Enterprise Value	8.75B

Important Dates

The next estimated earnings date is Friday, March 28, 2025.

Earnings Date	Mar 28, 2025
Ex-Dividend Date	n/a

Share Statistics

AIM Vaccine has 1.21 billion shares outstanding. The number of shares has increased by 0.25% in one year.

Current Share Class	n/a
Shares Outstanding	1.21B
Shares Change (YoY)	+0.25%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	28.20%
Owned by Institutions (%)	5.02%
Float	249.60M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.57
PB Ratio	1.88
P/TBV Ratio	2.79
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-6.84
EV / Sales	6.87
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-57.23

Financial Position

The company has a current ratio of 0.85, with a Debt / Equity ratio of 0.52.

Current Ratio	0.85
Quick Ratio	0.61
Debt / Equity	0.52
Debt / EBITDA	n/a
Debt / FCF	-13.78
Interest Coverage	-33.51

Financial Efficiency

Return on equity (ROE) is -39.44% and return on invested capital (ROIC) is -17.66%.

Return on Equity (ROE)	-39.44%
Return on Assets (ROA)	-14.13%
Return on Capital (ROIC)	-17.66%
Revenue Per Employee	817,208
Profits Per Employee	-821,151
Employee Count	1,624
Asset Turnover	0.15
Inventory Turnover	3.55

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -22.70% in the last 52 weeks. The beta is -0.29, so AIM Vaccine's price volatility has been lower than the market average.

Beta (5Y)	-0.29
52-Week Price Change	-22.70%
50-Day Moving Average	7.09
200-Day Moving Average	7.03
Relative Strength Index (RSI)	34.53
Average Volume (20 Days)	2,012,670

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AIM Vaccine had revenue of HKD 1.27 billion and -1.28 billion in losses. Loss per share was -1.06.

Revenue	1.27B
Gross Profit	-704.41M
Operating Income	-1.97B
Pretax Income	-2.28B
Net Income	-1.28B
EBITDA	-1.82B
EBIT	-1.97B
Loss Per Share	-1.06

Full Income Statement

Balance Sheet

The company has 704.16 million in cash and 2.11 billion in debt, giving a net cash position of -1.40 billion or -1.16 per share.

Cash & Cash Equivalents	704.16M
Total Debt	2.11B
Net Cash	-1.40B
Net Cash Per Share	-1.16
Equity (Book Value)	4.02B
Book Value Per Share	3.11
Working Capital	-465.48M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -14.67 million and capital expenditures -138.16 million, giving a free cash flow of -152.83 million.

Operating Cash Flow	-14.67M
Capital Expenditures	-138.16M
Free Cash Flow	-152.83M
FCF Per Share	-0.13

Full Cash Flow Statement

Margins

Gross margin is -55.36%, with operating and profit margins of -154.71% and -100.48%.

Gross Margin	-55.36%
Operating Margin	-154.71%
Pretax Margin	-179.03%
Profit Margin	-100.48%
EBITDA Margin	-142.93%
EBIT Margin	-154.71%
FCF Margin	n/a

Dividends & Yields

AIM Vaccine does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.25%
Shareholder Yield	-0.25%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AIM Vaccine has an Altman Z-Score of 2.26. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.26
Piotroski F-Score	n/a